Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Tokyo, Mitaka, Japan Clinical Trials

A listing of Tokyo, Mitaka, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC

Phase

0.57 miles

Learn More »

Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration

This phase I trial will involve 6 patients suffering from chronic ischemic cardiomyopathy and congestive heart failure, to be compared with historical control subjects. This study will be conducted as a collaborative project between the Sakakibara Heart Institute and the CellBank of Japan. The trial is designed to assess the ...

Phase

2.29 miles

Learn More »

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in Japanese patients with advanced and metastatic solid tumor. The dose escalation will follow the widely used 3+3 design. Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 ...

Phase

5.82 miles

Learn More »

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors.

Phase

7.43 miles

Learn More »

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

This is a Phase 1, multicenter, open-label study to evaluate safety, tolerability and pharmacokinetics of milademetan in Japanese patients with relapsed or refractory acute myeloid leukemia. The milademetan initial dose will be Level 1: 90 mg. No increase in the milademetan dose will be made in the same participant. Dose-limiting ...

Phase

7.43 miles

Learn More »

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients. PF-04449913 will be administered orally as a single agent in patients with select advanced hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or ...

Phase

7.55 miles

Learn More »

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

The drug being tested in this study is called TAK-831. This study will assess the safety, tolerability, pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-831 when administered as single or multiple oral doses in healthy adult Asian participants (Japanese and Chinese participants). The study will enroll approximately 32 participants and include ...

Phase

8.11 miles

Learn More »

Dose-escalation Trial of the Safety Pharmacokinetics and Pharmacodynamics of Iron Isomaltoside (Monofer )

IDA is highly prevalent in subjects with cancer and gastrointestinal diseases such as inflammatory bowel diseases, menstruating or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a substantial medical and quality of life (QoL) burden on the subjects, and treatment of these subjects includes controlling the ...

Phase

9.02 miles

Learn More »

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Subjects

The drug being tested in this study is called TAK-906. TAK-906 is being tested in healthy participants in order to evaluate safety and tolerability of single and multiple oral doses of TAK-906 in Japanese healthy male participants. The study will enroll approximately 24 patients. Participants will be randomly assigned (by ...

Phase

9.29 miles

Learn More »